Keith W Pratz, MD
Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
Attending Physician, Hospital of the University of Pennsylvania
Director, Leukemia Programs, University of Pennsylvania/Abramson Cancer Center
Department: Medicine
Contact information
3400 Civic Center Blvd.
South Pavilion Room 12-155
Philadelphia, PA 19104
South Pavilion Room 12-155
Philadelphia, PA 19104
Education:
BS (Molecular Biology)
University of Maryland at College Park, 1998.
MD (Medicine )
University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, 2002.
Permanent linkBS (Molecular Biology)
University of Maryland at College Park, 1998.
MD (Medicine )
University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, 2002.
Selected Publications
Pratz KW, Cherry M, Altman JK, Cooper BW, Podoltsev NA, Cruz JC, Lin TL, Schiller GJ, Jurcic JG, Asch A, Wu R, Hill JE, Gill SC, James AJ, Rich ES, Hasabou N, Perl AE, Levis MJ: Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML. J Clin Oncol Jun 2023.Matthews AH, Perl AE, Luger SM, Gill SI, Lai C, Porter DL, Skuli S, Bruno XJ, Carroll MP, Freyer CW, Carulli A, Babushok DV, Frey NV, Hexner EO, Martin ME, McCurdy SR, Stadtmauer EA, Loren AW, Paralkar VR, Maillard IP, Pratz KW: Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia. Am J Hematol Jun 2023.
Bhansali RS, Pratz KW, Lai C.: Recent advances in targeted therapies in acute myeloid leukemia. Journal of Hematology & Oncology Mar 2023.
Matthews A, Pratz KW: Optimizing outcomes in secondary AML. Hematology Am Soc Hematol Educ Program Dec 2022.
Connor MP, Loren AW, Hexner EO, Martin ME, Gill SI, Luger SM, Mangan JK, Perl AE, McCurdy SR, Pratz KW, Timlin C, Freyer CW, Carulli A, Catania C, Smith J, Hollander L, Zebrowski AM, Stadtmauer EA, Porter DL, Frey NV.: Clofarabine and busulfan myeloablative conditioning in allogeneic hematopoietic cell transplant for patients with active myeloid malignancies. Transplant Cell Ther. Nov 2022.
Matthews AH, Pratz KW, Carroll MP: Targeting Menin and CD47 to Address Unmet Needs in Acute Myeloid Leukemia. Cancers Nov 2022.
Pratz KW, Kaplan J, Levy M, Bixby D, Burke PW, Erba H, Wise-Draper TM, Roboz GJ, Papadantonakis N, Rajkhowa T, Hernandez D, Dobler I, Gregory RC, Li C, Wang S, Stumpo K, Kannan K, Miao H, Levis M.: A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia. Haematologica Oct 2022.
Pollyea DA, Pratz KW, Wei AH, Pullarkat V, Jonas BA, Recher C, Babu S, Schuh AC, Dail M, Sun Y, Potluri J, Chyla B, DiNardo CD.: Outcomes in Patients With Poor-risk Cytogenetics With or Without TP53 Mutations Treated With Venetoclax and Azacitidine. Clin Cancer Res Aug 2022.
Jonas BA, DiNardo C, Fracchiolla N, Pristupa A, Ishizawa K, Jin J, Konopleva M, Ofran Y, Montesinos P, Kovacsovics T, Jang JH, Kantarjian H, Duan Y, Potluri J, Werner M, Pratz KW.: Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study. Am J Hematol 2022.
Pratz KW, DiNardo CD, Selleslag D, Li J, Yamamoto K, Konopleva M, Stevens D, Kantarjian H, Traina F, Venditti A, Mayer J, Montez M, Jin H, Duan Y, Brackman D, Zha J, Potluri J, Werner M, Jonas BA.: Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A. Am J Hematol 2022.